Key Highlights

● Obsidian Therapeutics fell roughly 15% in a volatile session shortly after its Nasdaq debut, triggering Volatility trading halts.

● The pullback followed Obsidian's completion of a Reverse merger with Galera Therapeutics and a concurrent $350 million private placement.

● The $350 million placement, together with existing cash, is expected to fund the combined company's operations into the second half of 2028.

● Ownership splits roughly 51.6% legacy Obsidian, 47.2% private-placement investors and 1.2% legacy Galera, shaping the effective float and potential future supply.

Obsidian Therapeutics (NASDAQ: OBX) fell roughly 15% in a volatile session shortly after its Nasdaq debut, giving back a chunk of an outsized first-day gain as the newly public cell-therapy company found its footing on the market. The pullback followed Obsidian's completion of a reverse merger with Galera Therapeutics and a concurrent $350 million private Placement that recapitalized the combined company. Despite a well-funded Balance Sheet and a differentiated lead program, the stock swung sharply, triggering volatility trading halts, as early investors and traders repriced a thinly seasoned name in its first days of trading.

What Happened?

On August 3, 2026, Obsidian Therapeutics completed its previously announced Business combination with Galera Therapeutics, with the combined company operating as Obsidian Therapeutics, Inc. Shares began trading on Nasdaq under the ticker "OBX" on August 4, 2026. Concurrent with the closing, Obsidian completed a $350 million private placement, one of the larger financings tied to a biotech reverse merger this year.

The reverse-merger structure, common for private biotechs seeking a public listing, left former Obsidian stockholders with roughly 51.6% of the combined company, private placement investors with about 47.2%, and former Galera stockholders with approximately 1.2%. After an initial surge on its debut, the stock reversed sharply in subsequent sessions, and trading was paused multiple times for volatility around August 5–6 as the price whipsawed.

Why Is OBX Stock Falling?

The decline came as a newly Listed Stock digested an unusually strong debut. After jumping on its first day of trading, OBX gave back a large portion of that move, a pattern frequently seen in freshly public biotechs where early price discovery is volatile and the tradable float is limited. The repeated volatility halts underscore how thin and reactive the market was in those first sessions.

Importantly, the pullback does not appear tied to negative company-specific news. The merger closed as planned, the $350 million financing was completed, and the lead program's development timeline was reaffirmed. Instead, the move looks like post-debut normalization: an initial pop driven by Scarcity and momentum, followed by a give-back as broader Supply and profit-taking met the market. For a clinical-stage company with no product revenue, valuation in the first days of trading is inherently unsettled, and the wide intraday ranges, from the low-$20s to the mid-$30s in the debut week, reflect the market searching for a fair price rather than reacting to any operational setback.

The Numbers Investors Are Watching

The balance sheet is the headline figure: the $350 million private placement, together with existing cash, is expected to fund the combined company's operations into the second half of 2028, according to the company, a runway designed to carry key clinical readouts. That financing was backed by a broad syndicate of specialist healthcare investors alongside existing backers.

Investors are also watching the ownership split (roughly 51.6% legacy Obsidian, 47.2% private-placement investors, 1.2% legacy Galera), which shapes the effective float and potential future supply. Market Capitalization in the debut week hovered in the low-single-digit billions as the price swung, an unusually rich valuation for a pre-commercial biotech that adds to volatility. With no Revenue yet, the numbers that will ultimately matter are cash runway, clinical trial enrollment, and the timing of data readouts rather than traditional financial metrics.

The Bigger Picture

Obsidian's lead candidate is OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) cell therapy that incorporates a pharmacologically regulatable, membrane-bound form of interleukin-15 (IL-15), a design intended to enhance TIL activity while allowing control over its stimulation. The program has received both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration, regulatory signals that can support expedited development.

The Galera reverse merger is a well-trodden path for private biotechs to reach public markets without a traditional IPO, using a listed shell with cash and a Nasdaq listing. Galera, once focused on radiotherapy side-effect programs, effectively served as the public vehicle, contributing only a small residual ownership stake. Pairing the merger with a $350 million raise gave Obsidian a substantial war chest at the outset, a meaningful advantage in a capital-intensive cell-therapy field where funding gaps can derail promising programs. The financing drew a broad group of specialist healthcare funds alongside existing venture backers, a vote of confidence that also created a large pool of shares that could weigh on trading as the market absorbs the new float. TIL therapies, which harvest and expand a patient's own tumor-fighting immune cells, are complex to manufacture and administer, so execution risk remains high even with ample capital.

What Could Happen Next?

The key catalysts are clinical. Obsidian expects Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027, and registration-enabling data in melanoma by year-end 2027. Between now and then, investors will watch trial enrollment progress, any interim safety or efficacy disclosures, and updates on Manufacturing for the TIL therapy. As a newly public company, Obsidian will also file its first quarterly reports as OBX, offering the first detailed look at its cash position and Burn Rate following the $350 million raise. Near term, trading may remain volatile as the float settles and lock-up dynamics evolve; sustained direction will likely depend on clinical execution and the melanoma and lung-cancer timelines rather than on the debut-week price swings.

Bottom Line

Obsidian's roughly 15% drop reflects the turbulence typical of a biotech's first days as a public company rather than any setback in its underlying story. The confirmed facts, an August 3 merger close with Galera, an August 4 Nasdaq debut under OBX, a completed $350 million private placement, and cash guided to fund operations into the second half of 2028, point to a well-capitalized, pre-commercial cell-therapy company still in price discovery. The move followed an outsized debut gain and repeated volatility halts, not negative news. From here, the signals that matter are OBX-115 clinical progress, the NSCLC data expected in the first half of 2027, and melanoma readouts targeted for year-end 2027.

---